# Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions

> **NCT03616301** · PHASE1 · COMPLETED · sponsor: **Pharmtechnology LLC** · enrollment: 56 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Clavamox
- **DRUG:** Augmentin®

## Key facts

- **NCT ID:** NCT03616301
- **Lead sponsor:** Pharmtechnology LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-28
- **Primary completion:** 2018-08-13
- **Final completion:** 2018-08-13
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2018-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03616301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03616301, "Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03616301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*